FOR RESIDENT DOCTOR AND GENERAL PEDIATRICIAN, APPROCH TO SHORT STATURE AND MANAGEMENT OF SHORT STATURE FROM NELSON AND LATEST GUIDELINES
DR SIDDHARTHA JOSHI
DR JOSHI SIDDHARTHA
Everything You Need to Know About Short Stature in Children
1. SHORT STATURE
DR SIDDHARTHA JOSHI
MBBS,D.PAEDIATRIC(SETH GSMC medical college and
KEM hospital),DNB PAEDIATRICS (DELHI)
2. WHY WE NEED TO TALK ABOUT
SHORT STATURE
• 2-3% CHILD IN NORMAL POPULATION ARE
SHORT STATURE
• BECAUSE IT CAN BE A SIGN OF DISEASE OR
DISABILITY
• A SOCIAL STIGMA CAUSING PSYCHOLOGICAL
STRESS
3. WHAT IS SHORT STATURE
• LENGTH OR HEIGHT OF THE
CHILD BELOW 3RD CENTILE OR
-2SD OF THE EXPECTED OF
AGE AND SEX
• HOWEVER DIAGNOSIS
SHOULD BE MADE CAREFULLY
IN PREPUBERTAL CHILD AS
MAY BE THEY ARE SLOW
GROWERS
• IT IS DIFFERENT FROM
FAILURE TO THRIVE
4. CLASSIFICATION
• NORMAL VARIANT SS-20% CHILDREN WITH
NORMAL GROWTH POTENTIAL WHO ARE RELATIVELY SLOW
GROWERS IN CHILDHOOD BUT ACHIEVE NORMAL ADULT
HEIGHT BY MORE MARKED GROWTH SPURT DURING
ADOLESCENT OR DELAYED COMPLETION OF PUBERTY
• PRIMORDIAL SS-15 T0 20%CHILDREN WITH
INHERITEDLY LOW GROWTH POTENTIAL WHO REMAILN
SHORT STATURE EVEN AFTER COMPLETION OF PUBERTY
• SECONDARY SS-50 TO 60%-CHILDREN WITH
NORMAL GROWTH POTENTIAL WHICH IS HAMPERED BY
EXOGENEOUS FACTOR
5. ETIOLOGY
• PHYSIOLOGICAL(NORMAL VARIANT)-
FAMILIAL
CONSTITUTIONAL
• PRIMORDIAL SHORT STATURE-
GENETIC-CHROMOSOMAL,MONGOLISM,TURNER
INBORN ERROR OF METABOLISM-HURLER
OTHER-PROGERIA,SILVER RUSSEL SYNDROME
SKELETAL DYSPLASIA-SHORT LIMB-ACHONDOPLASIA
SHORT ARM-SPONDYLOEPIPHYSIAL DYSPLASIA
29. HOW TO MEASURE HEIGHT
• 0-2 YEAR
• SUPINE LENGTH-INFANTOMETER
• CHILD SHOULD BE RELAX
• HEAD FIRMLY PLACED AGAINST INFLEXIBLE BOARD
• LEGS FULLY EXTENDED AND FEET 90ANGLE TO LEG ON MOVABLE FLAT BOARD
• >2 YEAR-HARPENDER STADIOMETER(ACCURACY-0.1CM)
• CHILD SHOULD STAND ERECT WITH HEAD IN FRANKFURT PLANE
• HEEL SHOULD BE TOGETHER
• BACK OF HEAD,THORACIC SPINE,BUTTOCKS, AND HEEL SHOULD TOUCH THE VERTICAL
AXIS OF THE STADIOMETER
•
•
31. AGE OF PRESENTATION CAUSE OF SHORT STATURE
BIRTH TO 2 YEAR FAMILIAL SHORT
STATURE,RICKETS,SKELETAL
DYSLASIA,CHRONIC UNDER NUTRITION
2-5 YEAR UNTREATED CONGENITAL
HYPOTHYROIDISM,GROWTH HORMONE
DEFICIENCY,TURNER,CHRONIC SYSTEMIC
DISEASE
5-9 YEAR CONSTITUIONAL,CHRONIC SYSTEMIC
DISEASE
9 YEAR AND ABOVE FAMILIAL,SHORT STATURE,CHRONIC
SYSTEMIC DISEASE,ACQUIRED PRIMARY
HYPOTHYROIDISM,ACQUIRED GROWTH
HORMONE DEFICIENCY,RADIOTHERAPY
32. SCREENING TEST
• ANTHROPOMETRY
• CBC,HB,ESR
• BONE AGE
• RENAL AND LIVER FUNCTION TEST
• TOTAL PROTEIN , ALBUMIN
• S.CA,P,ALP
• BLOOD GAS, SERUM ELECTROLYTE
• SOMETO MEDIAN C,THYROID FUCTION,CORTISOL AND SEX
STEROID
• COELIAC SCREEN
• MAL ABSORPTION WORK UP
• IGF 1
• GENETIC STUDY
33. FAMILIAL CONSTITUTIONA
L
GENETIC SKELETAL SECONDARY ENDOCRINAL
PARENTAL
HEIGHT
LESS N N N N N
BIRTH WEIGHT N N LESS N N N
EARLY GV<3YR LESS LESS LESS LESS N/LESS N/LESS
LATE GV >3 YR N > 4CM/YEAR N >4CM/YEAR LESS LESS LESS N/LESS
ONSET OF
PUBERTY
N LATE N/LATE N N/LATE LATE/EARLY
FINAL ADULT
HRIGHT
LESS N LESS LESS N/LESS LESS
BODY
PRAPORTION
N N N DISPRAPORTINA
TE
N N/DISPRAPORTI
ONATE
WEIGHT FOR
HEIGHT
N N N MORE LESS MORE
BONE AGE VS CA N LESS N N LESS LESS
BONE AGE VS
HA
MORE N MORE MORE MORE LESS
34. IS THE CHILD
SHORT STATURE ?
YES
IS THE HEIGHT
WITHIN MPH
YES
BA=CA>HA
FAMILIAL
BA=HA<CA
CDGP
NO
ELICIT HISTORY TO
RULE OUT
SYSTEMIC
DISESEASES,MALNU
TRITION,IUGR,DYS
MORPHIC,CHROMO
SOMAL
SYNDROME,HORM
ONE DEFICIENCY
NO
REASSURANC
E AND ASSESS
GROWTH
VELOCITY
35. DISPRAPORTIONATE
SHORT STATURE
SHORT LIMB
PROXIMAL
RHIZOMELIC
ACHONDROPLESIA
HYPO CHONDROPLASIA
MIDDLE
MESOMELIC
SHOX
MESOMALIC
DYSPLASIA
DISTAL ACROMELIC
ELLISVAN CREVALD
SYNDROME
SHORT TRUNK
CONSIDER
MUCOPOLLYSACHA
RIDE
24 HOUR URINARY
COLLECTION,GENETIC
TESTING,CONSIDER
ENZYME REPLACEMENT
CLINICAL FEATURE
OF SHOX GENE
DEFECT
MUTATION
POSITIVE THAN
CONSIDER GH
DEFICIENCY
36. • CA=BA=HA
NORMAL CHILD
• CA=BA>HA
FAMILIAL OR
IDIOPATHIC
• CA>HA=BA
CDGP
• CA>HA>BA
ENDOCRINAL
DISORDERE
37. FEATURES FAMILIAL CONSTITUTIONAL
SEX BOTH EQUALLY AFFECTED MORE COMMON IN BOYS
LENGHT AT BIRTH NORMAL NORMAL
FAMILY HISTORY OF SHORT STATURE DELAYED PUBERTY
PARENT SHORT STATURE SHORT AVERAGE
HEIGHT VELOCITY NORMAL BUT GAIN >4
CM/YEAR
NORMAL
PUBERTY NORMAL DELAYED
BA AND CA BA=CA>HA CA>BA=HA
FINAL HEIGHT SHORT NORMAL
38. CHILD WITH CDGP
HEIGHT <3RD PERCENTILE FOR POPULATION OR FAMILY
CHRONOLOGICAL AGE >14 YEAR
SEVERE PHYSIOLOGICAL DISTRESS TO THE ADOLESCENT
CHILD WITH STAGE 1 OR2 TANNER SMR
NO
REAASURE Family
and FOLLOWUP
IN 6 MONTH
YES
TRIAL OF TESTOSTERON
THERAPY
TESTOSTERON 50 MG IM-
3 DOSES MONTHLY
STOP
THERAPY
NORMAL
PUBERTY NOT
RESUMED
EVALUATE
NORMAL PUBERTY
RESUMED
REASSURE FAMILY
39. CHILD WITH
FSS
MONITOR GROWTH
VELOCITY FOR 1 YEAR
GROWTH VELOCITY
>25TH CENTILE
CALCULATE PREDICTED
ADULT HEIGHT AND
HEIGHT SD SCORE
PREDICTED ADULT HEIGHT IS <150
CM IN GIRLS AND 160 CM IN BOYS
HEIGHT SD SCORE < -2.25
GH STIMULATION TEST
STIMULATED GH >10NG/ML
CONSIDER GH AS
PER ISS INDICATION
STIMULATED GH <10NG/ML
FAMILIAL GHD
GROWTH VELOCITY
<25TH CENTILE
EVALUATE
FOR
ASSOCIATED
PROBLEM
41. GROWTH HORMONE
• IN CHILDREN GHD IS DIAGNOSED ON
AUXOLOGY,CLINICAL FEATURES AND
BIOCHEMICAL PARAMETERS OF THE GROWTH
HORMONE GH-IGF1 AXIS.IT MAY PRESENT AS AN
ISOLATED DISORDER OR IN COMBINATION WITH
OTHER PITUTARY HORMONE DEFICIENCY.DUE TO
EPISODIC SECRETION OF GH,BESIDES
CIRCARDIAN RHYTHM AND WIDE INTRA AND
INTERINDIVIDUAL VARIATION IN GH
LEVELS,MEASUREMENT OF SINGLE GH VALUE IS
OF POOR DIAGNOSTIC VALUE.HENCE MANY
PROVOCATION TEST HAS BEEN EVALUATED
42. • INDICATION
• ON HISTORY-IN NEW BORN PERIOD HISTORY OF
HYPOGLYCEMIA,PROLONGED
JAUNDICE,MICROPHALLUS,BREECH
PRESENTATION,TRAUMATIC DELIVERY
• CRANIAL IRRADIATION,TUMOR
• HEAD TRAUMA,CNS INFECTION
• CRANIOFACIAL MEDLINE ABNORMALITY
• CONSANGUINITY AND OR AFFECTED FAMILY MEMBER
• SIGN OF MULTIPLE PITUTARY HORMONR DEFICIENCY
43. • AUXOLOGICAL ABNORMALITY—
• SEVERE SHORT STATURE
• HEIGHT MORE THAN 2SD BELOW MEAN AND A
HEIGHT VELOCITY MORE THAN 1 SD FOR
CHRONOLOGICAL OBSERVED OVER 1 YEAR
• IN THE ABSCENCE OF SHORT STATURE,A HEIGHT
VELOCITY OF MORE THAN 2SD BELOW MEAN
FOR OVER 1 YEAR OR MORE THAN 1.5 SD
BELOW MEAN SUSTAINED OVER 2 YEARS
44. • ABNORMAL SCREENING TEST
• WHEN OTHER CAUSES OF LOW IGF-1 LIKE
MALNUTRITION AND HYPOPROTEINEMIA
ARE EXCLUDED
45. • PREPARATION AND PRECAUTION
• 1.EVALUATION OF GHD SHOULD NOT BE INITIATED
UNTIL OTHER CAUSES OF SHORT STATURE ARE RULED
OUT
• 2.THYROID FUNCTION SHOULD BE NORMAL
• FASTING OVER NIGHT OR ATLEAST 8 HOUR PRIOR TO
THE TEST
• 4.BLOOD GLUCOSE SHOULD BE MONITOR
• 5.SEX STEROID PRIMING IF BONE AGE ABOVE 10
YEARS-GIVE 20 MICROGRAM ETHINYL ESTRadiol daily
in evening for 3 days and do test on 4th day
46. GH STIM TEST
STIMULUS DOSAGE SAMPLING FOR
HGH
REMARK ACCURACY
INSULIN -IV 0.05-0.1 U/KG IV -
30.0.15.30,45,60,
90,120
SEVERE
HYPOGLYCEMIA
85% AT CUT OFF
10NG/ML
CLONIDINE-ORAL 0.15
MICROGRAM/(M
)2
-
30.0.15.30,45,60,
90,120
DROWSINESS,HY
POTENSION
80%AT CUT OFF
10 NG/ML
ARGININE 10%IV 0.5 GM/KG IN
.9% NACL
-
30.0.15.30,45,60,
90,120
LATE
HYPOGLYCEMIA
75%AT CUT OFF
10 NG/ML
L-DOPA -PO <10 KG-125 MG
10-35 KG-250
MG
>35 KG-500 MG
-
30.0.15.30,45,60,
90,120
NAUSEA,VOMITI
NG,HEADACHE
80% AT CUTOOF
6 NG/ML
GLUCAGON-IM
OR SC
0.1
MICROGM/KG IM
0,60,90,120,150,
180
NAUSEA,VOMITI
NG,LATE
HYPOGLYCEMIA
47. • INTERPRETATION
• Peak gh response >10ng/ml exclude the
diagnosis of ghd
• Elevated basal and stimulated levvel of gh is
suggestive of gh insensitivity
• Gh neurosecretory dysfunction is suspected in
the presence of normal gh response with low
igf-1
48. GH THERAPY
GH recombinant human gh
0.05 mg/kg/day or 0.15 unit/kg/day till
skeletal maturity achieved or growth velocity
drop to <2cm/year
49. INDICATION OF GH THERAPY
• GROWTH HORMONE DEFICIENCY
• TURNER SYNDROME
• SHOX HAPLOINSUFFICIENCY
• SGA WITH FAILURE TO CATCH UP
• CHRONIC RENAL FAILURE
• PRADER WILLI
• IDIOPATHIC SHORT STATURE
50. SIDE EFFECT OF GH THERAPY
• PSEUDOTUMOR CEREBRI
• SLIPPED CAPITAL FEMORAL EPIPHYSIS
• HYPER GLYCEMIA
• HYPOTHYROIDISM
• ACUTE PANCREATITIS
• RISK OF MALIGNANCY
• OEDEMA-CARPAL TUNNEL SYNDROME
• GYNECOMASTIA
• WORSENING OF SCOLIOSIS
• THERE IS AN INCREASE IN TOTAL BODY WATER DURING FIRST TWO WEEK
OF TREATMENT
• RISK OF CRUETZFELDT JACOB SYNDROME AFTER 20 YEAR OF THERAPY
• THE DEVELOPMENT OF ANTIBODY
• COST OF RX- 2 LAKH PER YEAR